Trials / Terminated
TerminatedNCT05024903
A Novel E-health Platform
A Randomized Trial of a Novel E-health Platform (Plan Well GuideTM)
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Daren K. Heyland · Academic / Other
- Sex
- All
- Age
- 25 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the current trial is to evaluate a novel e-health platform. Overall Hypothesis: Participants who receive Plan Well Guide (PWG) 2.0 will make more progress in their 'preparations' as measured by "Preparedness for the Future Questionnaire (PREP FQ)" at 6 months and, consequently, experience greater improvements in their psychological well-being (PWB), health status, and life satisfaction at 12 months compared to participants receiving PWG 1.0 (Advance Serious Illness module only). Study Design: The investigators propose to conduct a multi-site randomized trial to evaluate a novel e-health platform. Overall Hypothesis: Participants who receive Plan Well Guide (PWG) 2.0 will make more progress in their 'preparations' as measured by "Preparedness for the Future Questionnaire (PREP FQ)" at 6 months and, consequently, experience greater improvements in their psychological well-being (PWB), health status, and life satisfaction at 12 months compared to participants receiving PWG 1.0 (Advance Serious Illness module only).Study Design: We propose to conduct a multi-site randomized trial. Setting: Several sites in Lethbridge Alberta. a sample of primary care clinics as well as recruit online participants. Study Population: The investigators plan to include interested participants that are aged between 25 to 70 years of age. We will exclude participants that don't speak English or do not have internet access/email addresses, and already have a high PWB score. Study Intervention: Eligible participants will then be randomly allocated to 2 groups: PWG 1.0 or PWG 2.0.Outcomes: The primary outcome for this trial will be an overall score of PWB questionnaire; key secondary outcomes include PWB domain scores, SF-12,single-item rating of life satisfaction, all measured at 6 and 12 months. Additional outcomes include 'days off work' and health care utilization. Significance: This study will be the first large multi-centre trial examining the effects of a novel e-health platform aimed at improving people's psychological well-being and health status as well as their preparedness for serious illness decision-making during this time of a global pandemic. Results of this trial will likely affect the state of preparedness of individuals, and if wide disseminated, may have a dramatic effect on the health and well-being of a broad segment of the population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Serious illness medical planning plus the novel e-health platform (PWG 2.0) | PWG 2.0 consists of the following components: 1. A diagnostic questionnaire, "Preparedness for the Future Questionnaire" and bench-marked report that helps users assess their strengths, weaknesses and opportunities for improvement. 2. A comprehensive e-workbook that helps users understand the science behind personal behavior change. 3. Links to webpages with additional e-workbooks and curated content aimed to help users progress on the 30 different attitudes, behaviors, and activities that portend for a better future (topics listed in Appendix A). 4. E-messages delivered via emails (via text an option for those that prefer) with tailored content designed to provide multiple nudges to guide the user to progress through our content. 5. Monthly newsletter with current topics and issues related to the 30 topics and behavior change in general. 6. A virtual consultation with Dr. Heyland, creator of PWG and principal investigator. |
| OTHER | Standard of care | Participants are not planning for their future (PWG 2.0) or using the e-health platform |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2022-09-22
- Completion
- 2022-09-22
- First posted
- 2021-08-27
- Last updated
- 2023-05-10
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05024903. Inclusion in this directory is not an endorsement.